Retisert (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Bausch Health  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
NCT00032396: A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

Unknown status
2
US
Retisert Implant
Control Delivery Systems, Bausch & Lomb Incorporated
Macular Degeneration
 
 
NCT00576459: Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema

Completed
2
40
RoW
0.59 mg fluocinolone acetonide intravitreal implant, Retisert, 2.1 mg fluocinolone acetonide intravitreal implant, standard of care laser photocoagulation
Bausch & Lomb Incorporated
Diabetic Macular Edema
06/06
07/06

Download Options